Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics

Celldex Therapeutics Inc. (CLDX): $26.41

0.56 (+2.17%)

POWR Rating

Component Grades













Add CLDX to Watchlist
Sign Up

Industry: Biotech



in industry


  • CLDX scores best on the Quality dimension, with a Quality rank ahead of 26.61% of US stocks.
  • The strongest trend for CLDX is in Momentum, which has been heading down over the past 179 days.
  • CLDX's current lowest rank is in the Sentiment metric (where it is better than 9.27% of US stocks).

CLDX Stock Summary

  • Celldex Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.06% of US listed stocks.
  • With a price/sales ratio of 358.22, Celldex Therapeutics Inc has a higher such ratio than 98.96% of stocks in our set.
  • As for revenue growth, note that CLDX's revenue has grown -37.3% over the past 12 months; that beats the revenue growth of only 4.58% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Celldex Therapeutics Inc, a group of peers worth examining would be FULC, SURF, FUSN, MRUS, and MIRM.
  • CLDX's SEC filings can be seen here. And to visit Celldex Therapeutics Inc's official web site, go to www.celldex.com.

CLDX Valuation Summary

  • CLDX's price/earnings ratio is -37.1; this is 201.64% lower than that of the median Healthcare stock.
  • Over the past 243 months, CLDX's EV/EBIT ratio has gone down 30.5.
  • Over the past 243 months, CLDX's price/earnings ratio has gone down 30.2.

Below are key valuation metrics over time for CLDX.

Stock Date P/S P/B P/E EV/EBIT
CLDX 2021-08-31 284.0 13.4 -37.1 -35.9
CLDX 2021-08-30 279.4 13.2 -36.5 -35.3
CLDX 2021-08-27 275.0 13.0 -35.9 -34.8
CLDX 2021-08-26 271.0 12.8 -35.4 -34.3
CLDX 2021-08-25 269.7 12.8 -35.2 -34.1
CLDX 2021-08-24 264.7 12.5 -34.5 -33.5

CLDX Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -63.94%.
  • Its 2 year cash and equivalents growth rate is now at -42.94%.
  • The 3 year revenue growth rate now stands at 9.45%.
CLDX's revenue has moved down $1,647,000 over the prior 70 months.

The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 4.651 -60.909 -70.511
2021-09-30 8.103 -51.597 -72.263
2021-06-30 8.618 -47.086 -66.035
2021-03-31 5.374 -46.378 -63.693
2020-12-31 7.418 -40.404 -59.78
2020-09-30 4.519 -46.193 -48.327

CLDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
  • CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
  • CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.

The table below shows CLDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 1 -0.480
2021-03-31 0.022 1 -0.447
2020-12-31 0.034 1 -0.479
2020-09-30 0.024 1 -0.470
2020-06-30 0.028 1 -0.636
2020-03-31 0.038 1 -0.864

CLDX Price Target

For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $64.83 Average Broker Recommendation 1.25 (Strong Buy)

CLDX Stock Price Chart Interactive Chart >

Price chart for CLDX

CLDX Price/Volume Stats

Current price $26.41 52-week high $57.20
Prev. close $25.85 52-week low $25.17
Day low $25.36 Volume 249,614
Day high $26.89 Avg. volume 570,796
50-day MA $32.34 Dividend yield N/A
200-day MA $39.04 Market Cap 1.23B

Celldex Therapeutics Inc. (CLDX) Company Bio

Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.

CLDX Latest News Stream

Event/Time News Detail
Loading, please wait...

CLDX Latest Social Stream

Loading social stream, please wait...

View Full CLDX Social Stream

Latest CLDX News From Around the Web

Below are the latest news stories about Celldex Therapeutics Inc that investors may wish to consider to help them evaluate CLDX as an investment opportunity.

Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | March 1, 2022

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

GlobeNewswire | February 28, 2022

Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 28, 2022

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights.

GlobeNewswire | February 22, 2022

Celldex Therapeutics (CLDX) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

Read More 'CLDX' Stories Here

CLDX Price Returns

1-mo -17.65%
3-mo -12.40%
6-mo -33.32%
1-year -4.10%
3-year 730.50%
5-year -42.46%
YTD -31.65%
2021 120.55%
2020 685.65%
2019 -25.67%
2018 -92.96%
2017 -19.77%

Continue Researching CLDX

Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:

Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7205 seconds.